Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 960-967

  Evans, Martin E ^a,b   Feola, David J ^c   Rapp, Robert P ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Colistimethate; Polymyxin B sulfate

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; GRAM NEGATIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXIN B;

EID: 0032826448     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18426     Document Type: Review

References (102)

1. Edgar WM, Dickinson KM. A trail of colistin methane sulphonate in urinary infection with Pseudomonas pyocyanea. Lancet 1962;1:739-40.
2. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
3. Fass RJ, Barnisham J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995;36:343-53.
4. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechmvsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998;39: 53-62.
5. Hsueh PR, Teng LJ, Yang PC, Chen YC, Ho SW, Luh KT. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 1998;36:1347-51.
6. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993;31:919-26.
7. Krcmery V, Trupl J. Nosocomial outbreak of meropenem resistant Pseudomonas aeruginosa infections in a cancer centre. J Hosp Infect 1994; 26:69-78.
8. Armstrong D, Neu H, Peterson LR, Tomasz A. The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990's. Microb Drug Resist 1995;1:1-4.
9. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Ann Rev Biochem 1977;46:723-63.
10. Package insert. Polymyxin B sulfate sterile, 500,000 units. Bedford, OH: Bedford Laboratories, 1998.
11. Taylor G, Allison H. "Colomycin" - laboratory and clinical investigations. Brit Med J 1962;2:161-3.
12. Cox CE, Harrison LH. Intravenous sodium colistimethate therapy of urinary-tract infections: pharmacological and bacteriological studies. Antimicrob Agents Chemother 1970:296-302.
13. Baines RD Jr, Rifkind D. Intravenous administration of sodium colistimethate. JAMA 1964;190:278-81.
14. Package insert. Coly-Mycin M parenteral (sterile colistimethate sodium, USP). Morris Plains, NJ: Parke-Davis Division of Warner-Lambert Co., 1995.
15. Meyers E, Parker WL, Brown WE, Linnett P, Strominger JL. EM49: a new polypeptide antibiotic active against cell membranes. Ann N Y Acad Sci 1974;235:493-501.
16. Chihara S, Tobita T, Yahata M, Ito A, Koyama Y. Enzymatic degradation of colistin isolation and identification of alpha-N-acyl alpha, lambda-diaminobutyric acid and colistin nonapeptide. Agr Biol Chem 1973; 37:2455-63.
17. Rosenthal KS, Swanson PE, Storm DR. Disruption of Escherichia coli outer membranes by EM 49. A new membrane active peptide antibiotic. Biochemistry 1976;15:5783-92.
18. Viljanen P, Vaara M. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrob Agents Chemother 1984;25:701-5.
19. Nord NM, Hoeprich PD. Polymyxin B and colistin. N Engl J Med 1964; 270:1030-5.
20. Urena MTP, Barasoain I, Espinosa M, Garcia E. Evaluation of different antibiotic actions combined with rifampicin. Chemotherapy 1975;21:82-9.
21. Traub WH, Kleber I. In vitro additive effect of polymyxin B and rifampin against Serratia marcescens. Antimicrob Agents Chemother 1975;7:874-6.
22. Diaz CR, Fossieck BE, Parker RH. Pseudomonas endocarditis: cure with carbenicillin and polymyxin B. South Med J 1977;70:869-71.
23. Klastersky J, Cappel R, Debusscher L, Daneau D, Swings G. Use of carbenicillin and polymyxin B for therapy of gram-negative bacilli infections. Chemotherapy 1971;16:269-75.
24. Eickhoff T, Finland M. Polymyxin B and colistin: in vitro activity against Pseudomonas aeruginosa. Am J Med Sci 1965;249:172-4.
25. LaPorte DC, Rosenthal KS, Storm DR. Inhibition of Escherichia coli growth and respiration by polymyxin B covalently attached to agarose beads. Biochemistry 1977;16:1642-7.
26. Leive L. Part II. Functional inter-relationships of walls and membranes. The barrier function of the gram-negative envelope. Ann N Y Acad Sci 1974;235:109-29.
27. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979;18:4425-30.
28. Chen C-CH, Feingold DS. Locus of divalent cation inhibition of the bactericidal action of polymyxin B. Antimicrob Agents Chemother 1972;2: 331-5.
29. Newton BA. Site of action of polymyxin on Pseudomonas aeruginosa: antagonism by cations. J Gen Microbiol 1954;10:491-99.
30. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis 1971;124:610-2.
31. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976;13:813-8.
32. Bader J, Teuber M. Action of polymyxin B on bacterial membranes, I. Binding to the O-antigenic lipopolysaccharide of Salmonella typhimurium. Z Naturforsch [C] 1973;28c:422-30.
33. Peterson AA, Hancock REW, McGroarty EJ. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol 1985;164:1256-61.
34. Lopes J, Inniss WE. Electron microscopy of effect of polymyxin on Escherichia coli lipopolysaccharide. J Bacteriol 1969;100:1128-30.
35. Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J Bacteriol 1969;97:448-52.
36. Iida K, Koike M. Cell wall alterations of gram-negative bacteria by aminoglycoside antibiotics. Antimicrob Agents Chemother 1974;5:95-7.
37. Schinder PRG, Teuber M. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and in the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob Agents Chemother 1975;8:95-104.
38. Lounatmaa K, Nanninga N. Effect of polymyxin on the outer membrane of Salmonella typhimurium: freeze-fracture studies. J Bacteriol 1976; 128:665-7.
39. Mandal TK. Electron microscopic study of the polymyxin treated Vibrio cholerae cells. Z Naturforsch [C] 1990;45:902-10.
40. Davis SD, Iannetta A, Wedgwood RJ. Paradoxical synergism and antagonism between serum and the antibacterial activity of colistin. J Infect Dis 1971;123:392-8.
41. Fierer J, Finley F. Lethal effect of complement and lysozyme on polymyxin-treated, serum-resistant gram-negative bacilli. J Infect Dis 1979; 140:581-9.
42. Pruul H, Reynolds BL. Interaction of complement and polymyxin with gram-negative bacteria. Infect Immun 1972;6:709-17.
43. Hancock REW, Wong PGW. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 1984;26:48-52.
44. Wahn K, Lutsch G, Rockstroh T, Zapf K. Morphological and physiological investigations on the action of polymyxin B on Escherichia coli. Arch Mikrobiologie 1968;63:103-16.
45. Schröder G, Brandenburg K, Seydel U. Polymyxin B induces transient permeability fluctuations in asymmetric planar lipopolysaccharide/phospholipid bilayers. Biochemistry 1992;31:631-8.
46. Mäkelä PH, Sarvas M, Calcagno S, Lounatmaa K. Isolation and genetic characterization of polymyxin-resistant mutants of Salmonella. FEMS Microbiol Lett 1978;3:323-6.
47. Brown MRW, Fenton EM, Watkins WM. Tetracycline-sensitive/polymyxin-resistant Pseudomonas aeruginosa (letter). Lancet 1972;2:86.
48. Conrad RS, Galanos C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob Agents Chemother 1989;33:1724-8.
49. Vaara M, Vaara T, Sarvas M. Decreased binding of polymyxin-resistant mutants of Salmonella typhimurium. J Bacteriol 1979;139:664-7.
50. Vaara M, Vaara T, Jensen M, Helander I, Nurminen M, Rietschel ET, et al. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett 1981;129: 145-9.
51. Brown MRW, Watkins WM. Low magnesium and phospholipid content of cell walls of Pseudomonas aeruginosa resistant to polymyxin. Nature 1970;227:1360-1.
52. Nicas TI, Hancock REW. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980; 143:872-8.
53. Shand GH, Anwar H, Brown MRW. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: effect of magnesium depletion. J Antimicrob Chemother 1988;22:811-21.
54. Gudmundsson S, Craig WA. Role of antibiotics in endotoxin shock. In: Proctor RA, ed. Handbook of endotoxin. Vol. 4: clinical aspects of endotoxin shock. Amsterdam: Elsevier Science Publishers B.V.;1986:238-63.
55. Cooperstock MS. Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother 1974;6:422-5.
56. Butler T, Möller G. Mitogenic response of mouse spleen cells and gelation of limulus lysate by lipopolysaccharide of Yersinia pestis and evidence for neutralization of the lipopolysaccharide by polymyxin B. Infect Immun 1977;18:400-4.
57. Morrison DC, Jacobs DM. Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B. Infect Immun 1976;13: 298-301.
58. Jacobs DM, Morrison DC. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J Immunol 1977;118:21-7.
59. Nel AE, Wooten MW, Goldschmidt-Clermont PJ, Miller PJ, Stevenson HC, Galbraith RM. Polymyxin B causes coordinate inhibition of phorbol ester-induced C-kinase activity and proliferation of B lymphocytes. Biochem Biophys Res Commun 1985;128:1364-72.
60. Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WEI. Interferon-lambda induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol 1986;136:963-9.
61. Lasfargues A, Tahri-Jouti M-A, Pedron T, Girard R, Chaby R. Effects of lipopolysaccharide on macrophages analyzed with anti-lipid A monoclonal antibodies and polymyxin B. Eur J Immunol 1989;19:2219-25.
62. Stokes DC, Shenep JL, Fishman M, Hildner WK, Bysani GK, Rufus K. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis 1989;160: 52-9.
63. Cavaillon J-M, Haeffner-Cavaillon N. Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin. Mol Immunol 1986;23:965-9.
64. Corrigan JJ Jr, Bell BM. Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect Immun 1971;4:563-6.
65. Corrigan JJ Jr, Bell BM. Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate. J Lab Clin Med 1971;77:802-10.
66. Craig WA, Turner JH, Kunin CM. Prevention of the generalized Shwartzman reaction and endotoxin lethality by polymyxin B localized in tissues. Infect Immun 1974;10:287-92.
67. Täuber MG, Shibl AM, Hackbarth CJ, Larrick JW, Sande MA. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits. J Infect Dis 1987;156:456-62.
68. Mustafa MM, Ramilo O, Syrogiannopoulos GA, Olsen KD, McCracken GH Jr, Hansen EJ. Induction of meningeal inflammation by outer membrane vesicles of Haemophilus influenzae type B. J Infect Dis 1989;159: 917-22.
69. Wispelwey B, Hansen EJ, Scheld WM. Haemophilus influenzae outer membrane vesicle-induced blood-brain barrier permeability during experimental meningitis. Infect Immun 1989;57:2559-62.
70. Syrogiannopoulos GA, Hansen EJ, Erwin AL, Munford RS, Rutledge J, Reisch JS, et al. Haemophilus influenzae type B lipooligosaccharide induces meningeal inflammation. J Infect Dis 1988;157:237-44.
71. Baldwin G, Alpert G, Caputo GL, Baskin M, Parsonnet J, Gillis ZA, et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis 1991;164:542-9.
72. Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987;156:706-12.
73. Walterspiel JW, Kaplan SL, Mason EO Jr. Protective effect of subinhibitory polymyxin B alone and in combination with ampicillin for overwhelming Haemophilus influenzae type B infection in the infant rat: evidence for in vivo and in vitro release of free endotoxin after ampicillin treatment. Pediatr Res 1986;20:237-41.
74. Corrigan JJ, Kiernat JF. Effect of polymyxin B sulfate on endotoxin activity in a gram-negative septicemia model. Pediatr Res 1979;13:48-51.
75. Bysani GK, Stokes DC, Fishman M, Shenep JL, Hildner WK, Rufus K, et al. Binding of polymyxin B to rat alveolar macrophages. J Infect Dis 1990;162:939-43.
76. Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 1989;168:323-31.
77. Kucers A, Bennett NM. Polymyxins. In: Kucers A, Bennett NM, eds. The use of antibiotics. A comprehensive review with clinical emphasis. 4th ed. Philadelphia: Lippincott;1987:905-17.
78. Kunin CM. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med 1967;67:151-8.
79. Hoeprich PD. The polymyxins. Med Clin North Am 1970;54:1257-65.
80. Goodwin NJ. Colistin and sodium colistimethate. Med Clin North Am 1970;54:1267-76.
81. Feeley TW, du Moulin GC, Hedley J, Bushnell LS, Gilbert JP, Feingold DS. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975;293:471-5.
82. Dickie KJ, de Groot WJ. Ventilatory effects of aerosolized kanamycin and polymyxin. Chest 1973;63:694-7.
83. Kagan BM, Krevsky D, Milzer A. Polymyxin B and polymyxin E: clinical and laboratory studies. J Lab Clin Med 1951;37:402-14.
84. Kaplan RS, Fisher AE, Kahn JL. Treatment of pertussis with polymyxin B (aerosporin). J Pediatr 1949;35:49-57.
85. Goodwin NJ, Friedman EA. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 1968;68:984-94.
86. Greenberg PA, Sanford JP. Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate. Ann Intern Med 1967; 66:465-79.
87. MacKay DN, Kaye D. Serum concentrations of colistin in patients with normal and impaired renal function. N Engl J Med 1964;270:394-7.
88. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24:362-79.
89. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971;124:394-400.
90. Craig WA, Kunin CM. Dynamics of binding and release of the polymyxin antibiotics by tissues. J Pharmacol Exp Ther 1973;184:757-65.
91. Pedersen MF, Pedersen JF, Madsen PO. A clinical and experimental comparative study of sodium colistimethate and polymyxin B sulfate. Invest Urol 1971;9:234-7.
92. Price DJE, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. Brit Med J 1970;4:525-7.
93. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-4.
94. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med 1962;266:759-62.
95. Lindesmith LA, Baines DR, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med 1957;68:318-27.
96. Koch-Weser J, Sidel VW, Federman EB. Adverse effects of sodium colistimethate. Manifestations and specific rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
97. Pohlmann G. Respiratory arrest associated with intravenous administration of polymyxin B sulfate. JAMA 1966;196:167-9.
98. Ryan KJ, Schainuck LI, Hickman RO, Striker GE. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 1969; 207:2099-101.
99. Perkins RL. Apnea with intramuscular colistin therapy. JAMA 1964; 190:421-4.
100. Marschke G, Sarauw A. Danger of polymyxin B inhalation. Ann Intern Med 1971;74:296-7.
101. Lieberson AD, Winter LW, Behnke RH, Martin RR. Extensive pseudomonal pneumonia ultimately responding to polymyxin therapy. Am Rev Resp Dis 1969;100:558-64.
102. Hayashi K. Other antibiotics. Clin Orthop 1984;190:109-13.